Test Id : META3
Metanephrines with 3-Methoxytyramine, 24 Hour, Urine
Useful For
Suggests clinical disorders or settings where the test may be helpful
A first- and second-tier screening test for the presumptive diagnosis of catecholamine-secreting pheochromocytomas and paragangliomas
Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.
| Test Id | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 3MT1 | 3-Methoxytyramine, U | Yes, (Order 3MT) | Yes |
| METAF | Metanephrines, Fractionated, 24h, U | Yes | Yes |
Method Name
A short description of the method used to perform the test
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
3-methoxy-4-hydroxyphenethylamine
3-Methoxytramine
3-Methoxytyramine
3MT
Fractionated metanephrines
Free Metanephrine
Metanephrines free, urine
Methoxytramine
Methoxytyramine
NMN (Normetanephrines), urine
Normetanephrine, (NMN), free
Normetanephrines, urine
Urine Dopamine
Specimen Type
Describes the specimen type validated for testing
Urine
Necessary Information
24-Hour volume (in milliliters) is required.
ORDER QUESTIONS AND ANSWERS
| Question ID | Description | Answers |
|---|---|---|
| TM50 | Collection Duration (h) | |
| VL48 | Volume (mL) |
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Patient Preparation: Tricyclic antidepressants, labetalol, and sotalol medications may elevate levels of metanephrines producing results that cannot be interpreted. If clinically feasible, it is optimal to discontinue these medications at least 1 week before collection. For advice on assessing the risk of removing patients from these medications and alternatives, consider consultation with a specialist in endocrinology or hypertension.
Supplies: Urine Tubes, 10 mL (T068)
Submission Container/Tube: Plastic urine tube
Specimen Volume: 10 mL
Collection Instructions:
1. Complete 24-hour urine collections are preferred, especially for patients with episodic hypertension; ideally the collection should begin at the onset of a "spell."
2. Add 10 g (pediatric: 3 g) of boric acid or 25 mL (pediatric: 15 mL) of 50% acetic acid as preservative at start of collection.
3. Collect urine for 24 hours.
Special Instructions
Library of PDFs including pertinent information and forms related to the test
Urine Preservative Collection Options
Note: The addition of preservative or application of temperature controls must occur at the start of the collection.
| Ambient | OK |
| Refrigerate | OK |
| Frozen | OK |
| 50% Acetic Acid | Preferred |
| Boric Acid | Preferred |
| Diazolidinyl Urea | No |
| 6M Hydrochloric Acid | OK |
| 6M Nitric Acid | No |
| Sodium Carbonate | OK |
| Thymol | No |
| Toluene | OK |
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
4 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | OK |
| Gross icterus | OK |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Urine | Refrigerated (preferred) | 28 days | |
| Ambient | 21 days | ||
| Frozen | 28 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
A first- and second-tier screening test for the presumptive diagnosis of catecholamine-secreting pheochromocytomas and paragangliomas
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Pheochromocytomas and paragangliomas (Pheo/PGL) are rare, usually benign, tumors of chromaffin cells in the adrenal medulla or paragangliomas (estimated population prevalence rates of 1 in 200,000 with a yearly incidence rate of 1-2/1000), that are potentially lethal, because they secrete excessive, uncontrolled amounts of catecholamines (dopamine, epinephrine, and norepinephrine) resulting in often severe hypertension and many cardiac abnormalities. A subgroup of these patients will also suffer tumor recurrence and sometimes malignant behavior. Untreated, these tumors have substantial morbidity and mortality.
Key symptoms are episodes of hypertension with palpitations, severe headaches, and sweating (spells). However, some patients might be asymptomatic, have mild symptoms that might be missed, or have sustained hypertension, which is frequently observed in these patients. Finally, due to the high frequency of medical imaging for unrelated ailments, increasing numbers of occult small adrenal tumors are often incidentally discovered, some of which might be Pheo/PGLs.
3-Methoxytyramine (3MT), metanephrine, and normetanephrine are the metabolites of dopamine, epinephrine, and norepinephrine, respectively. These metabolites are further metabolized to vanillylmandelic acid. Pheochromocytoma cells also have the ability to oxymethylate catecholamines into metanephrines, which are secreted into circulation and urine. 3MT is only elevated in a small proportion of patients with Pheo/PGL. Because of its low levels testing is performed using only 24-hour urine specimens at this time, while epinephrine, and norepinephrine can be measured in plasma or 24-hour urine specimens.
An early childhood malignancy that arises from immature neuroendocrines in the adrenals, called neuroblastoma, shares many features of Pheo/PGL but has the added threat of a high malignancy rate; however, there are also frequent spontaneous remissions, particular in very young infants.
Biochemical testing for neuroblastoma differs from Pheo/PGL because of many specific issues in testing infants and young children, using urine tests rather than blood tests.
For all Pheo/PGL, the preferred initial testing is by plasma metanephrine testing, as it has the highest clinical sensitivity thus facilitating ruling out Pheo/PGL, if the test results are within the healthy population reference range. However, in potentially familial cases, or monitoring of treated patients some additional and repeated testing may be required.
Testing for 24-hour urine metanephrine plus urinary catecholamine levels may be used as a confirmatory study in patients with less than a 2-fold elevation in plasma free fractionated catecholamines. This is highly desirable, as the very low population incidence rate of Pheo/PGL (<1:200,000 population per year) will otherwise result in large numbers of unnecessary, costly, and sometimes risky imaging procedures.
Finally, familial Pheo/PGL probably accounts for a higher proportion of cases than previously thought; at least 30% are now believed to be familial. The corollary of this is that about 20 to 30 seemingly sporadic cases are likely familial. Given these statistics, genetic testing for index cases and family members should be considered.
Treatment consists of surgical tumor removal after pharmaceutical alpha-adrenergic blockade, which may be supplemented with beta blockade once the alpha blockade has been established. This preparation is aimed to prevent massive catecholamine surges during surgery.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
3-Methoxytyramine:
Males: < or =306 mcg/24 h
Females: < or =242 mcg/24 h
METANEPHRINE
Males
Normotensives
3-8 years: 29-92 mcg/24 h
9-12 years: 59-188 mcg/24 h
13-17 years: 69-221 mcg/24 h
> or =18 years: 44-261 mcg/24 h
Reference values have not been established for patients that are younger than 36 months.
Hypertensives: <400 mcg/24 h
Females
Normotensives
3-8 years: 18-144 mcg/24 h
9-12 years: 43-122 mcg/24 h
13-17 years: 33-185 mcg/24 h
> or =18 years: 30-180 mcg/24 h
Reference values have not been established for patients that are younger than 36 months.
Hypertensives: <400 mcg/24 h
NORMETANEPHRINE
Males
Normotensives
3-8 years: 34-169 mcg/24 h
9-12 years: 84-422 mcg/24 h
13-17 years: 91-456 mcg/24 h
18-29 years: 103-390 mcg/24 h
30-39 years: 111-419 mcg/24 h
40-49 years: 119-451 mcg/24 h
50-59 years: 128-484 mcg/24 h
60-69 years: 138-521 mcg/24 h
> or =70 years: 148-560 mcg/24 h
Reference values have not been established for patients that are younger than 36 months.
Hypertensives: <900 mcg/24 h
Females
Normotensives
3-8 years: 29-145 mcg/24 h
9-12 years: 55-277 mcg/24 h
13-17 years: 57-286 mcg/24 h
18-29 years: 103-390 mcg/24 h
30-39 years: 111-419 mcg/24 h
40-49 years: 119-451 mcg/24 h
50-59 years: 128-484 mcg/24 h
60-69 years: 138-521 mcg/24 h
> or =70 years: 148-560 mcg/24 h
Reference values have not been established for patients that are younger than 36 months.
Hypertensives: <900 mcg/24 h
TOTAL METANEPHRINE
Males
Normotensives
3-8 years: 47-223 mcg/24 h
9-12 years: 201-528 mcg/24 h
13-17 years: 120-603 mcg/24 h
18-29 years: 190-583 mcg/24 h
30-39 years: 200-614 mcg/24 h
40-49 years: 211-646 mcg/24 h
50-59 years: 222-680 mcg/24 h
60-69 years: 233-716 mcg/24 h
> or =70 years: 246-753 mcg/24 h
Reference values have not been established for patients that are younger than 36 months.
Hypertensives: <1300 mcg/24 h
Females
Normotensives
3-8 years: 57-210 mcg/24 h
9-12 years: 107-394 mcg/24 h
13-17 years: 113-414 mcg/24 h
18-29 years: 142-510 mcg/24 h
30-39 years: 149-535 mcg/24 h
40-49 years: 156-561 mcg/24 h
50-59 years: 164-555 mcg/24 h
60-69 years: 171-616 mcg/24 h
> or =70 years: 180-646 mcg/24 h
Reference values have not been established for patients that are younger than 36 months.
Hypertensives: <1300 mcg/24 h
For International System of Units (SI) conversion for Reference Values, see www.mayocliniclabs.com/order-tests/si-unit-conversion.html
Interpretation
Provides information to assist in interpretation of the test results
Further clinical investigation (eg, radiographic studies) and genetic studies might be warranted in patients whose 3-methoxytyramine (3MT), metanephrine, or normetanephrine are elevated or when there is a very high clinical index of suspicion.
Increased 3MT levels are found in patients with pheochromocytoma and dopamine-secreting tumors.
3MT levels of 306 mcg/24 h or less in male patients and 242 mcg/24 h or less in female patients can be detected in non-pheochromocytoma hypertensive patients.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Tricyclic antidepressants, labetalol, and sotalol medications may elevate levels of metanephrines producing results that cannot be interpreted. If clinically feasible, it is optimal to discontinue these medications at least 1 week before collection.
This test utilizes a liquid chromatography tandem mass spectrometry method and is not affected by the interfering substances that affected older spectrophotometric (Pisano reaction) methods (ie, diatrizoate, chlorpromazine, hydrazine derivatives, imipramine, monoamine oxidase inhibitors, methyldopa, phenacetin, ephedrine, or epinephrine) or high-performance liquid chromatography methods (acetaminophen).
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Muskiet FA, Thomasson CG, Gerding AM, Fremouw-Ottevangers DC, Nagel GT, Wolthers BG. Determination of catecholamines and their 3-O-methylated metabolites in urine by mass fragmentography with use of deuterated internal standards. Clin Chem. 1979;25(3):453-460
2. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem. 2002;48(3):533-539.
3. Roden M, Raffesberg W, Raber W, et al. Quantification of unconjugated metanephrines in human plasma without interference by acetaminophen. Clin Chem. 2001;47(6):1061-1067
4. Sawka AM, Singh RJ, Young WF Jr. False positive biochemical testing for pheochromocytoma caused by surreptitious catecholamine addition to urine. The Endocrinologist. 2001;11(5):421-423
5. van Duinen N, Steenvoorden D, Kema IP, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab. 2010;95(1):209-214
6. Le Jacques A, Abalain JH, Le Saos F, Carre JL. Interet du dosage urinaire de la 3-methoxytyramine dans le diagnostic des pheochromocytomes et paragangliomes: a propos de 28 cas [Significance of 3-methoxytyramine urine measurement in the diagnosis of pheochromocytomas and paragangliomas: about 28 patients]. Ann Biol Clin (Paris). 2011;69(5):555-559. doi:10.1684/abc.2011.0612
7. Lam L, Woollard GA, Teague L, Davidson JS. Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers. Ann Clin Biochem. 2017;54(2):264-272
8. Hirsch D, Grossman A, Nadler V, Alboim S, Tsvetov G. Pheochromocytoma: Positive predictive values of mildly elevated urinary fractionated metanephrines in a large cohort of community-dwelling patients. J Clin Hypertens (Greenwich). 2019;21(10):1527-1533. doi:10.1111/jch.13657
9. Gupta PK, Marwaha B. Pheochromocytoma. In: StatPearls [Internet]. StatPearls Publishing; 2024. Updated March 5, 2023. Accessed April 22, 2024. Available at www.ncbi.nlm.nih.gov/books/NBK589700
Method Description
Describes how the test is performed and provides a method-specific reference
Urine samples are acidified and hydrolyzed in a heat block, then metanephrine and normetanephrine are extracted from the specimens utilizing extraction cartridges. Analyte concentrations are determined through analysis performed by a liquid chromatography tandem mass spectrometry method.(Unpublished Mayo method)
Urinary 3-methoxytyramine is determined by reverse-phase liquid chromatography tandem mass spectrometry with stable isotope dilution analysis.(Unpublished Mayo method)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
82542
83835
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| META3 | Metanephrines with 3-MT, 24h, U | 101400-0 |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 8552 | Metanephrine, U | 104629-1 |
| 21545 | Normetanephrine, U | 104631-7 |
| 83006 | Total Metanephrines, U | 104630-9 |
| TM50 | Collection Duration (h) | 13362-9 |
| VL48 | Volume (mL) | 3167-4 |
| 2434 | Comment | 48767-8 |
| 609422 | 3-Methoxytyramine, U | 32618-1 |